Combined-modality treatment of locally advanced non-small cell lung cancer: Incorporation of novel chemotherapeutic agents

Keyphrases

• Combined Modality Therapy 100%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 100%
• Non-small Cell Lung Cancer (NSCLC) 40%
• Surgical Resection 40%
• Local Control 40%
• Accelerated Radiotherapy 40%
• Tumor 20%
• Weight Loss 20%
• Overall Survival 20%
• Survival Rate 20%
• Palliation 20%
• Patient Selection 20%
• Patient Survival 20%
• Carboplatin 20%
• Paclitaxel 20%
• Surgery Alone 20%
• Performance Status 20%
• Minimal Impact 20%
• Clinical Research 20%
• Active Agent 20%
• Platinum Compounds 20%
• Novel Agents 20%
• Induction Chemotherapy 20%
• Chemotherapy Regimen 20%
• Thoracic Radiation Therapy 20%
• Locally Advanced 20%
• Distant Control 20%
• Irinotecan 20%
• Thoracic Radiation 20%
• Combined Modality 20%
• Thoracic Radiotherapy 20%
• Gemcitabine 20%
• Taxanes 20%
• Vinorelbine 20%
• Exact Sequence 20%
• Locally Advanced Disease 20%
• N2 Disease 20%
• Sequential Chemotherapy 20%
• Minimal Weight 20%

Medicine and Dentistry

• Non Small Cell Lung Cancer 100%
• Chemotherapy 100%
• Radiation Therapy 42%
• Disease 28%
• Surgery 28%
• Paclitaxel 28%
• Multimodality Cancer Therapy 28%
• Chemoradiotherapy 28%
• Neoplasm 14%
• Low Drug Dose 14%
• Overall Survival 14%
• Symptom 14%
• Survival Rate 14%
• Symptomatic Treatment 14%
• Clinical Research 14%
• Carboplatin 14%
• Gemcitabine 14%
• Induction Chemotherapy 14%
• Chemotherapy Regimens 14%
• Vinorelbine 14%
• Platinum Derivative 14%
• Irinotecan 14%
• Hyperfractionated Accelerated Radiotherapy 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Non Small Cell Lung Cancer 100%
• Disease 28%
• Chemotherapy 28%
• Paclitaxel 28%
• Chemoradiation Therapy 28%
• Neoplasm 14%
• Symptom 14%
• Survival Rate 14%
• Carboplatin 14%
• Overall Survival 14%
• Clinical Research 14%
• Gemcitabine 14%
• Platinum Derivative 14%
• Irinotecan 14%
• Chemotherapy Regimens 14%
• Vinorelbine 14%
• Taxane 14%